Canada Communicable Disease Report

Published by Infectious Disease and Control Branc (IDPCB) - Public Health Agency of Canada

Online ISSN: 1481-8531

·

Print ISSN: 1188-4169

Articles


Figure 1. Cases of Salmonella Enteritidis SENXAI.0003, SENBNI.0003, PT 8, by date of symptom onset, New Brunswick, Nova Scotia, and Prince Edward Island, August 2004 to July 2005 (n = 17) Figure 1. Cas d'infection à Salmonella Enteritidis SENXAI.0003, SENBNI.0003, lt 8, selon la date d'apparition des symptômes, Nouveau-Brunswick, Nouvelle-Écosse et Île-du-Prince-Édouard, d'août 2004 à juillet 2005 (n = 17)  
Figure 2. Cases of Salmonella Enteritidis SENXAI.0003, SENBNI.0003, PT 8, by by location of exposure and dateof onset, New Brunswick, Nova Scotia, and Prince Edward Island, August 2004 to July 2005 (n = 17) Figure 2. Cas d'infection à Salmonella Enteritidis SENXAI.0003, SENBNI.0003, lt 8, selon le lieu d'exposition et la date d'apparition des symptômes, Nouveau-Brunswick, Nouvelle-Écosse et Île-du-Prince-Édouard, d'août 2004 à juillet 2005 (n = 17)  
Table 2. HAV cases by occupation 
Figure 2. Dendrogram depicting fbAFLP analysis of S. pneumoniae isolates. Clusters A and B denote outbreak cases Figure 2. Représentation graphique de l'analyse fAFLP d'isolats de S. pneumoniae. Les grappes A et B renvoient aux cas associés à l'éclosion  
Home or away? Investigation of Salmonella enteritidis PFGE pattern SENXAI.0003 and SENBNI.0003, phage type 8, the in the Maritimes, 2005
  • Article
  • Full-text available

November 2006

·

160 Reads

A Currie

·

·

W MacDonald

·

[...]

·

L Panaro
Download
Share


An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Update: statement on influenza vaccination for the 2003-04 season

April 2004

·

105 Reads

The National Advisory Committee on Immunization (NACI) provides Health Canada with ongoing and timely medical, scientific, and public health advice relating to immunization. Health Canada acknowledges that the advice and recommendations set out in this statement are based upon the best current available scientific knowledge and is disseminating this document for information purposes. People administering or using the vaccine should also be aware of the contents of the relevant product monograph(s). Recommendations for use and other information set out herein may differ from that set out in the product monograph(s) of the Canadian licensed manufacturer(s) of the vaccine(s). Manufacturer(s) have sought approval of the vaccine(s) and provided evidence as to its safety and efficacy only when it is used in accordance with the product monographs.























Top-cited authors